Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Collen

Showing results (661-670 of 715) with videos related to

Pageof 72
Sort By:
Human Gene Therapy|July 13, 2000
Percutaneous gene therapy using recombinant adenoviruses encoding human herpes simplex virus thymidine kinase, human PAI-1, and human NOS3 in balloon-injured porcine coronary arteriesO Varenne, P Sinnaeve, H Gillijns, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|October 13, 2001
L-arginine administration reduces neointima formation after stent injury in rats by a nitric oxide-mediated mechanismP Vermeersch, Z Nong, E Stabile, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 1, 1984
Biological properties of human tissue-type plasminogen activator obtained by expression of recombinant DNA in mammalian cellsD Collen, J M Stassen, B J Marafino, et al.
Journal of the American College of Cardiology|August 1, 1993
Short-term effects of early intravenous treatment with a beta-adrenergic blocking agent or a specific bradycardiac agent in patients with acute myocardial infarction receiving thrombolytic therapyF Van de Werf, L Janssens, T Brzostek, et al.
Lancet (London, England)|April 13, 1985
Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen ActivatorM Verstraete, R Bernard, M Bory, et al.
Journal of the American College of Cardiology|April 1, 1988
Detection of coronary artery reperfusion with creatine kinase-MB determinations during thrombolytic therapy: correlation with acute angiographyH D Garabedian, H K Gold, T Yasuda, et al.
The Journal of Clinical Investigation|August 1, 1990
Pharmacodynamic study of F(ab')2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectorisH K Gold, L W Gimple, T Yasuda, et al.
Circulation|May 1, 1984
Improvement of regional myocardial metabolism after coronary thrombolysis induced with tissue-type plasminogen activator or streptokinaseB E Sobel, E M Geltman, A J Tiefenbrunn, et al.
American Heart Journal|August 1, 1997
Randomized coronary patency trial of double-bolus recombinant staphylokinase versus front-loaded alteplase in acute myocardial infarctionS Vanderschueren, J Dens, P Kerdsinchai, et al.
Klinische Wochenschrift|January 1, 1988
[Randomized double-blind study comparing tissue-type plasminogen activator with placebo in acute myocardial infarct]W Bleifeld, M Verstraete, R W Brower, et al.
Pageof 72

Showing results (661-670 of 715) with videos related to

Sort By:
Pageof 72
Human Gene Therapy|July 13, 2000
Percutaneous gene therapy using recombinant adenoviruses encoding human herpes simplex virus thymidine kinase, human PAI-1, and human NOS3 in balloon-injured porcine coronary arteriesO Varenne, P Sinnaeve, H Gillijns, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|October 13, 2001
L-arginine administration reduces neointima formation after stent injury in rats by a nitric oxide-mediated mechanismP Vermeersch, Z Nong, E Stabile, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 1, 1984
Biological properties of human tissue-type plasminogen activator obtained by expression of recombinant DNA in mammalian cellsD Collen, J M Stassen, B J Marafino, et al.
Journal of the American College of Cardiology|August 1, 1993
Short-term effects of early intravenous treatment with a beta-adrenergic blocking agent or a specific bradycardiac agent in patients with acute myocardial infarction receiving thrombolytic therapyF Van de Werf, L Janssens, T Brzostek, et al.
Lancet (London, England)|April 13, 1985
Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen ActivatorM Verstraete, R Bernard, M Bory, et al.
Journal of the American College of Cardiology|April 1, 1988
Detection of coronary artery reperfusion with creatine kinase-MB determinations during thrombolytic therapy: correlation with acute angiographyH D Garabedian, H K Gold, T Yasuda, et al.
The Journal of Clinical Investigation|August 1, 1990
Pharmacodynamic study of F(ab')2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectorisH K Gold, L W Gimple, T Yasuda, et al.
Circulation|May 1, 1984
Improvement of regional myocardial metabolism after coronary thrombolysis induced with tissue-type plasminogen activator or streptokinaseB E Sobel, E M Geltman, A J Tiefenbrunn, et al.
American Heart Journal|August 1, 1997
Randomized coronary patency trial of double-bolus recombinant staphylokinase versus front-loaded alteplase in acute myocardial infarctionS Vanderschueren, J Dens, P Kerdsinchai, et al.
Klinische Wochenschrift|January 1, 1988
[Randomized double-blind study comparing tissue-type plasminogen activator with placebo in acute myocardial infarct]W Bleifeld, M Verstraete, R W Brower, et al.
Pageof 72